Department of Liver Surgery, Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu, China.
Cancer Med. 2023 Apr;12(8):9213-9227. doi: 10.1002/cam4.5662. Epub 2023 Feb 1.
The surgical indications and therapeutic strategies for early-stage multifocal and recurrent hepatocellular carcinoma (rHCC) remain controversial. This study compared the long-term outcome of patients with recurrent and multifocal HCC meeting the Barcelona Clinic Liver Cancer (BCLC) stage A with repeat hepatectomy (RH) and RH combined with intraoperative radiofrequency ablation (RFA).
A total of 109 consecutive patients with intrahepatic early-stage multifocal rHCC within BCLC stage A following RH or RH + RFA were retrospectively collected from April 2010 to May 2020. Propensity score matching, subgroup analysis, and univariate and multivariate analyses were performed. Overall survival after recurrence (rOS) and recurrence-free survival after recurrence (rRFS) were calculated by Kaplan-Meier analysis.
The 1-, 3-, and 5-year rOS and rRFS of the combination group and the RH group were similar (p = .699; p = .587, respectively). The similar results also appeared in matched population. Subgroup analyses indicated that there was no significant difference between patients with two tumors and three tumors, but the RH group was associated with better rRFS than the combination group for patients whose tumors were located in the same lobe (p = .045). Multivariate analysis revealed that time to recurrence (TTR) ≤ 2 years and intrahepatic metastasis (IM) pathologically were independent risk factors.
For multifocal rHCC patients meeting the BCLC stage A, tumor which is difficult to be surgically resected could be treated by RFA in order to avoid complications or bleeding. Tumors which were located in the same lobe may be more suitable to be treated by RH alone.
对于符合巴塞罗那临床肝癌(BCLC)分期 A 标准的早期多灶性和复发性肝细胞癌(rHCC),其手术适应证和治疗策略仍存在争议。本研究比较了符合 BCLC 分期 A 标准且接受再次肝切除术(RH)或 RH 联合术中射频消融术(RFA)的复发性多灶性 HCC 患者的长期预后。
从 2010 年 4 月至 2020 年 5 月,回顾性收集了 109 例因 RH 后或 RH+RFA 后肝内早期多灶性 rHCC 而符合 BCLC 分期 A 的连续患者。采用倾向评分匹配、亚组分析、单因素和多因素分析。采用 Kaplan-Meier 分析计算复发后的总生存(rOS)和复发后无复发生存(rRFS)。
联合组和 RH 组的 1、3 和 5 年 rOS 和 rRFS 相似(p=0.699;p=0.587)。匹配人群也出现了相似的结果。亚组分析表明,对于肿瘤数量为 2 个和 3 个的患者,两组之间没有显著差异,但对于肿瘤位于同一叶的患者,RH 组的 rRFS 优于联合组(p=0.045)。多因素分析显示,复发时间(TTR)≤2 年和肝内转移(IM)病理是独立的危险因素。
对于符合 BCLC 分期 A 的多灶性 rHCC 患者,如果肿瘤难以手术切除,可以采用 RFA 治疗,以避免并发症或出血。位于同一叶的肿瘤可能更适合单独采用 RH 治疗。